TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22348399

Group type: EXPERIMENTAL
Intervention: GP endorsed reminder and duplicate FOBt kit
Number of subjects: 4380

Group type: COMPARATOR
Intervention: No additional contact
Number of subjects: 4380
Study: 20346716

Group type: EXPERIMENTAL
Intervention: PedMIDAS
Number of subjects: 1585
Study: 17424883

Group type: EXPERIMENTAL
Intervention: Absorbable dressing
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard nonabsorbable sinus packs
Number of subjects: 35
Study: 16359284

Group type: EXPERIMENTAL
Intervention: Paced QRS duration <190 ms (Group A, n=77)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Paced QRS duration >=190 ms (Group B, n=15)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Paced QRS duration
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Paced QRS duration among group A patients with CHF during follow-up
Number of subjects: 92
Study: 12577242

Group type: EXPERIMENTAL
Intervention: Amifostine (200 mg/m2/d before radiation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (radiation therapy 64.8 Gy, paclitaxel, carboplatin, followed by cisplatin and gemcitabine)
Number of subjects: 0
Study: 15335530

Group type: EXPERIMENTAL
Intervention: 0.15% aqueous alcohol solution
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.10% aqueous alcohol solution
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.05% aqueous alcohol solution
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.05% aqueous alcohol solution (1 ml)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.10% aqueous alcohol solution (1 ml)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.15% aqueous alcohol solution (1 ml)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 38
Study: 7975842

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine expressed in mutant yeast (non-hyperglycosylated preS2 + 2 polypeptide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensed HB vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperglycosylated preS2 + 2 vaccine
Number of subjects: 0
Study: 2633660

Group type: EXPERIMENTAL
Intervention: Vialon catheter
Number of subjects: 170

Group type: COMPARATOR
Intervention: Teflon catheter
Number of subjects: 170
Study: 30502508

Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28761069

Group type: EXPERIMENTAL
Intervention: Biomarker-positive patients receiving FDA-approved oncology drugs with required pharmacogenomic biomarker testing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-enriched randomized controlled trials
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-enriched studies (non-randomized)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Biomarker-negative patients
Number of subjects: 80
Study: 26811103

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU vitamin D3 every 14 days for four months)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 24812309

Group type: EXPERIMENTAL
Intervention: Intensive counselling
Number of subjects: 297

Group type: COMPARATOR
Intervention: Routine counselling
Number of subjects: 297
Study: 22102701

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 46
Study: 19203570

Group type: EXPERIMENTAL
Intervention: diclofenac-cholestyramine 140 mg capsule formulation
Number of subjects: 26
Study: 17363401

Group type: EXPERIMENTAL
Intervention: 110 mg epicutaneous ketoprofen in 4.8 g Transfersome
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: 100 mg oral celecoxib
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 15371062

Group type: EXPERIMENTAL
Intervention: Client-centered therapy for childhood traumatic grief (CTG)
Number of subjects: 1
Study: 11430439

Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (830nm) at a dosage of 9 J/cm2
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 9
Study: 9651460

Group type: EXPERIMENTAL
Intervention: HIV infected subjects (n=9)
Number of subjects: 78

Group type: COMPARATOR
Intervention: HIV exposed but uninfected subjects (n=69)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: HIV infected subjects (n=7)
Number of subjects: 78
Study: 8564320

Group type: EXPERIMENTAL
Intervention: CBT + buspirone
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo + CBT
Number of subjects: 91
Study: 2297460

Group type: EXPERIMENTAL
Intervention: Oxazepam (15 mg) + Propranolol (80 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxazepam (15 mg) + Labetalol (200 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxazepam (15 mg) + Propranolol (80 mg) + Labetalol (200 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Labetalol (200 mg)
Number of subjects: 6
Study: 791584

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2alpha
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 28
Study: 31209957

Group type: EXPERIMENTAL
Intervention: Perineal pudendal nerve block + periprostatic nerve block (group 3)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Intrarectal local anesthesia + periprostatic nerve block (group 2)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Periprostatic nerve block (group 1)
Number of subjects: 148
Study: 28659293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: 1 mg Fe · kg‐1 · d‐1
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: 2 mg Fe · kg‐1 · d‐1
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Iron supplementation (combined 1 or 2 mg Fe · kg‐1 · d‐1)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: DBP
Number of subjects: 285
Study: 25952050

Group type: EXPERIMENTAL
Intervention: Experimental handwash formulations (sand)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soap and water
Number of subjects: 0
Study: 24431806

Group type: EXPERIMENTAL
Intervention: 4 % Articaine hydrochloride with 1:100,000 epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2 % Lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study: 21835957

Group type: EXPERIMENTAL
Intervention: Pediatric-inspired GRAALL trial
Number of subjects: 232

Group type: COMPARATOR
Intervention: LALA-94 trial
Number of subjects: 232
Study: 18535785

Group type: EXPERIMENTAL
Intervention: INO-1001
Number of subjects: 40
Study: 17420682

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 15566922

Group type: EXPERIMENTAL
Intervention: Truncated exponential biphasic waveform (360 J)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Rectilinear biphasic waveform (200 J)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Truncated exponential biphasic waveform (360 J) after crossover
Number of subjects: 145
Study: 11430708

Group type: EXPERIMENTAL
Intervention: CeraLyte‐90 (n = 85)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Glucose ORS (n = 82)
Number of subjects: 167
Study: 9489539

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulins
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Patients with preceding gastrointestinal illness, initial predominant distal weakness, acute motor neuropathy, or anti-GM1 antibodies
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Patients with treatment related fluctuations
Number of subjects: 172
Study: 1537493

Group type: EXPERIMENTAL
Intervention: Liquid meal alone (700 kcal)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Liquid meal in combination with propranolol
Number of subjects: 13
Study: 6373157

Group type: EXPERIMENTAL
Intervention: oxpentifylline (200 mg 3-times daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 31148494

Group type: EXPERIMENTAL
Intervention: Radial Shockwave Therapy (rSWT) + Standard Orthotic Management (SOM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Radial Shockwave Therapy (rSWT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Orthotic Management (SOM)
Number of subjects: 60
Study: 29557855

Group type: EXPERIMENTAL
Intervention: Long-term medication-assisted treatment (LT-MAT) with buprenorphine/naloxone
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Short-term medication-assisted treatment (C)
Number of subjects: 1250
Study: 27522034

Group type: EXPERIMENTAL
Intervention: Action-planning intervention
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (standard trial protocol)
Number of subjects: 800
Study: 23054805

Group type: EXPERIMENTAL
Intervention: Mango peels and seed kernels with urea block
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mango kernels
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diets containing mango residues
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mango peels
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mango seed kernels
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control diet (straw only)
Number of subjects: 25
Study: 20961967

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/day, n=34)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Metformin (1000 mg/day, n=33)
Number of subjects: 67
Study: 20633407

Group type: EXPERIMENTAL
Intervention: Active tDCS treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham tDCS treatment
Number of subjects: 7
Study: 17701857

Group type: EXPERIMENTAL
Intervention: Sonographic examination after 3 months of abstinence therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Evaluation by independent experts
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mean pixel intensity ratio of liver to kidney
Number of subjects: 59
Study: 14675243

Group type: EXPERIMENTAL
Intervention: PFL therapy (13 mg/m2 CDDP, 300 mg/m2 5-FU, 30 mg/body weight LV for 5 consecutive days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: FL therapy (300 mg/m2 5-FU, 30 mg/body weight LV for 5 consecutive days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: FL therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PFL therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PFL therapy and FL therapy
Number of subjects: 31
Study: 11399714

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (RBC transfusions at hemoglobin concentration of 7.0 g/dL, maintained between 7.0 g/dL and 9.0 g/dL)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (RBC transfusions at hemoglobin concentration of 10.0 g/dL, maintained between 10.0 g/dL and 12.0 g/dL)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 713

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy in patients with mechanical ventilation for > 7 days
Number of subjects: 713
Study: 9579845

Group type: EXPERIMENTAL
Intervention: Combined intravenous and intraperitoneal chemotherapy with FU/LV (LV 200 mg m(‐2) plus FU 350 mg m(‐2), administered intravenously on days 1-4 and intraperitoneally on days 1 and 3 every 4 weeks for a total of six courses)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Standard therapy with FU and levamisole (given for a duration of 6 months)
Number of subjects: 241
Study: 7660219

Group type: EXPERIMENTAL
Intervention: Methimazole 30 mg once daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propylthiouracil 100 mg every 8 hours
Number of subjects: 22
Study: 2755345

Group type: EXPERIMENTAL
Intervention: Mestranol (mean 26 micrograms/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 201937

Group type: EXPERIMENTAL
Intervention: MSH/ACTH4‐10
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diluent control
Number of subjects: 20
Study: 31635757

Group type: EXPERIMENTAL
Intervention: Bilateral erector spinae plane block
Number of subjects: 3
Study: 28056894

Group type: EXPERIMENTAL
Intervention: Intensive bespoke group-based diet and physical activity intervention
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intensive bespoke group-based diet and physical activity intervention with enhanced support from diabetes prevention mentors (DPM)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control arm receiving no trial intervention
Number of subjects: 135
Study: 25988924

Group type: EXPERIMENTAL
Intervention: Histopathological diagnosis
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Review of clinical features, treatment, and prognosis
Number of subjects: 2
Study: 23735597

Group type: EXPERIMENTAL
Intervention: Midwives' antenatal clinic service
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine antenatal care by obstetricians and obstetric nurses
Number of subjects: 110
Study: 21257251

Group type: EXPERIMENTAL
Intervention: Mechanical Resuscitation Device (MRD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard Basic Life Support (BLS)
Number of subjects: 39
Study: 19278581

Group type: EXPERIMENTAL
Intervention: Thymosin alpha1 (1.6 mg subcutaneous injection per day for 7 days)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Combined therapy (CBP + thymosin alpha1)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (classical Surviving Sepsis Campaign therapy)
Number of subjects: 91
Study: 16551931

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined continuous femoral and sciatic nerve blocks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 12766751

Group type: EXPERIMENTAL
Intervention: Mediterranean dietary advice
Number of subjects: 131

Group type: COMPARATOR
Intervention: No specific dietary advice (Control)
Number of subjects: 131
Study: 10699226

Group type: EXPERIMENTAL
Intervention: Haloperidol (medicated state)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Haloperidol-free period (drug-free state)
Number of subjects: 21
Study: 9555126

Group type: EXPERIMENTAL
Intervention: Combination therapy (sulfasalazine, prednisolone, and methotrexate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfasalazine alone
Number of subjects: 0
Study: 7894897

Group type: EXPERIMENTAL
Intervention: Treatment of herpetic keratitis
Number of subjects: 0
Study: 2974630

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (SCT) 100 IU, administered four times a week for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (1 ml saline), administered four times a week for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo group later receiving salmon calcitonin
Number of subjects: 42
Study: 29584496

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of Alprazolam and Hydrocodone/Acetaminophen
Number of subjects: 8
Study: 28476207

Group type: EXPERIMENTAL
Intervention: amygdalar rtfMRI-nf
Number of subjects: 34

Group type: COMPARATOR
Intervention: control parietal rtfMRI-nf
Number of subjects: 34
Study: 26805495

Group type: EXPERIMENTAL
Intervention: Thera-Band exercise program in addition to conventional CPM exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional CPM exercise only
Number of subjects: 30
Study: 23031657

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide nasal spray (TANS)
Number of subjects: 41
Study: 21487150

Group type: EXPERIMENTAL
Intervention: 1 g of vitamin C daily during training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19735378

Group type: EXPERIMENTAL
Intervention: Immediate HRT (tibolone 2.5 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Delayed HRT (tibolone 2.5 mg)
Number of subjects: 38
Study: 17023156

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha and interleukin-2 (arm A)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Two cycles of dacarbazine monotherapy followed by the same 4-drug regimen of chemoimmunotherapy (arm B)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy after two cycles of dacarbazine in arm B
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall survival comparison between arms A and B
Number of subjects: 93
Study: 12813202

Group type: EXPERIMENTAL
Intervention: 99mTc-DTPA lung scan before HD
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 99mTc-DTPA lung scan after HD
Number of subjects: 24
Study: 11004846

Group type: EXPERIMENTAL
Intervention: bFGF in BAL from s.A (1.79 pg/ml) and s.B (1.48 pg/ml) in sarcoidosis patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VEGF in BAL from s.A (107.5 pg/ml) and s.B (109.7 pg/ml) in sarcoidosis patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: bFGF in BAL from s.A in active sarcoidosis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Concentrations of bFGF in BAL from both s.A and s.B
Number of subjects: 28
Study: 9133694

Group type: EXPERIMENTAL
Intervention: 131I treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithyroid drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of 131I treatment and early thyroxine
Number of subjects: 0
Study: 8396179

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 4024920

Group type: EXPERIMENTAL
Intervention: Balanced glucose infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 19
Study: 29903785

Group type: EXPERIMENTAL
Intervention: Internet-mediated cognitive behavioural therapy (ICBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment as usual (TaU)
Number of subjects: 90
Study: 27034111

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 32
Study: 25458712

Group type: EXPERIMENTAL
Intervention: Bilateral tDCS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bilateral tDCS with CIMT
Number of subjects: 34

Group type: COMPARATOR
Intervention: CIMT alone
Number of subjects: 34
Study: 23872720

Group type: EXPERIMENTAL
Intervention: Intravenous sivelestat, n = 8
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous saline, n = 8
Number of subjects: 16
Study: 21149431

Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia or death
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical variables associated with the outcome
Number of subjects: 0
Study: 19004200

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (points: Baihui (GV 20), Shenting (GV 24), Yintang (EX‐HN 3), Shuigou (GV 26), Hegu (LI 4), Taichong (LR 3), Shenmen (HT 7), Neiguan (PC 6) supplemented by electroacupuncture)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Alprazolam (oral administration)
Number of subjects: 67
Study: 16644710

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 0
Study: 14728760

Group type: EXPERIMENTAL
Intervention: Online assessment via low-bandwidth Internet link (18 kbit/s)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Online assessment via higher-speed Internet link (128 kbit/s)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional assessment from video-recordings
Number of subjects: 24
Study: 11764828

Group type: EXPERIMENTAL
Intervention: 36% phosphoric acid (PA) for 15 s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 36% phosphoric acid (PA) for 7 s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-rinse conditioner (NRC) for 20 s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 17% EDTA for 60 s
Number of subjects: 40

Group type: COMPARATOR
Intervention: 17% EDTA
Number of subjects: 40
Study: 8905205

Group type: EXPERIMENTAL
Intervention: Simvastatin and low cholesterol diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 17
Study: 1915427

Group type: COMPARATOR
Intervention: Enalapril (5 mg twice daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pimobendan (5 mg twice daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pimobendan
Number of subjects: 24

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 24
Study: 6271846

Group type: EXPERIMENTAL
Intervention: delta 9‐Tetrahydrocannabinol (THC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: prochlorperazine
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study: 31264451

Group type: EXPERIMENTAL
Intervention: Mental Contrasting with Implementation Intentions (MCII)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Government-promoted control strategy
Number of subjects: 346
Study: 31433355

Group type: EXPERIMENTAL
Intervention: E2 vaginal inserts (4, 10, or 25?g)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study: 27237772

Group type: EXPERIMENTAL
Intervention: Uphill treadmill training for 30 minutes daily for 6 weeks
Number of subjects: 32
Study: 25866811

Group type: EXPERIMENTAL
Intervention: Ursolic acid liposome (UAL) at 56 mg/m2
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ursolic acid liposome (UAL) at 74 mg/m2
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ursolic acid liposome (UAL) at 98 mg/m2
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ursolic acid liposome (UAL) at 74 mg/m2 for pharmacokinetics
Number of subjects: 29
Study: 23889716

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10355